(Q37257900)

19 August 2017

1 reference

title

The early bactericidal activity of anti-tuberculosis drugs: a literature review (English)

1 reference

19 August 2017

0 references

P R Donald

1

1 reference

PubMed ID

18762155

19 August 2017

A H Diacon

series ordinal

2

1 reference

PubMed ID

18762155

19 August 2017

language of work or name

1 reference

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

88 Suppl 1

1 reference

19 August 2017

S75-83

1 reference

The enumeration of viable tubercle bacilli in cultures and infected tissues

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis; results of simultaneous sensitivity tests in liquid and on solid media

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Chemotherapy of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Activity of amoxicillin/clavulanate in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Bactericidal Activity of Streptomycin, Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Alone and In Combination Against Mycobacterium Tuberculosis1

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Sources of variation in studies of the early bactericidal activity of antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

A reiterative method for calculating the early bactericidal activity of antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Early bactericidal activity of antituberculosis agents

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970038-6

7 January 2021

10.1016/S1472-9792(08)70038-6

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18762155